<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">54582</article-id><article-id pub-id-type="doi">10.7554/eLife.54582</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>Activin A forms a non-signaling complex with ACVR1 and type II Activin/BMP receptors via its finger 2 tip loop</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-189996"><name><surname>Aykul</surname><given-names>Senem</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-169692"><name><surname>Corpina</surname><given-names>Richard A</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-169693"><name><surname>Goebel</surname><given-names>Erich J</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-189997"><name><surname>Cunanan</surname><given-names>Camille J</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-169694"><name><surname>Dimitriou</surname><given-names>Alexandra</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-169695"><name><surname>Kim</surname><given-names>Hyonjong</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-169696"><name><surname>Zhang</surname><given-names>Qian</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-169697"><name><surname>Rafique</surname><given-names>Ashique</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" id="author-169698"><name><surname>Leidich</surname><given-names>Raymond</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-169699"><name><surname>Wang</surname><given-names>Xin</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf7"/></contrib><contrib contrib-type="author" id="author-169714"><name><surname>McClain</surname><given-names>Joyce</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf8"/></contrib><contrib contrib-type="author" id="author-119068"><name><surname>Jimenez</surname><given-names>Johanna</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf9"/></contrib><contrib contrib-type="author" id="author-119062"><name><surname>Nannuru</surname><given-names>Kalyan C</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf10"/></contrib><contrib contrib-type="author" id="author-169701"><name><surname>Rothman</surname><given-names>Nyanza J</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf11"/></contrib><contrib contrib-type="author" id="author-169702"><name><surname>Lees-Shepard</surname><given-names>John B</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1275-5799</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf12"/></contrib><contrib contrib-type="author" id="author-168923"><name><surname>Martinez-Hackert</surname><given-names>Erik</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-169703"><name><surname>Murphy</surname><given-names>Andrew J</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="conf13"/></contrib><contrib contrib-type="author" id="author-169704"><name><surname>Thompson</surname><given-names>Thomas B</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-180479"><name><surname>Economides</surname><given-names>Aris N</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6508-8942</contrib-id><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="fn" rid="conf14"/></contrib><contrib contrib-type="author" corresp="yes" id="author-169691"><name><surname>Idone</surname><given-names>Vincent</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="fn" rid="conf15"/></contrib><aff id="aff1"><institution content-type="dept">Skeletal Diseases TFA</institution>, <institution>Regeneron Pharmaceuticals</institution>, <addr-line><named-content content-type="city">Tarrytown</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Skeletal Diseases Therapeutic Focus Area</institution>, <institution>Regeneron Pharmaceuticals</institution>, <addr-line><named-content content-type="city">Tarrytown</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">Department of Molecular Genetics, Biochemistry, and Microbiology</institution>, <institution>University of Cincinnati</institution>, <addr-line><named-content content-type="city">Cincinnati</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><institution content-type="dept">Therapeutic Antibodies</institution>, <institution>Regeneron Pharmaceuticals</institution>, <addr-line><named-content content-type="city">Tarrytown</named-content></addr-line>, <country>United States</country></aff><aff id="aff5"><institution content-type="dept">Bioassay, Molecular Biology, and Protein Development</institution>, <institution>Regeneron Pharmaceuticals</institution>, <addr-line><named-content content-type="city">Tarrytown</named-content></addr-line>, <country>United States</country></aff><aff id="aff6"><institution content-type="dept">Genome Engineering Technologies</institution>, <institution>Regeneron Pharmaceuticals</institution>, <addr-line><named-content content-type="city">Tarrytown</named-content></addr-line>, <country>United States</country></aff><aff id="aff7"><institution>Michigan State University</institution>, <addr-line><named-content content-type="city">East Lansing</named-content></addr-line>, <country>United States</country></aff><aff id="aff8"><institution content-type="dept">Research &amp; Development</institution>, <institution>Regeneron Pharmaceuticals</institution>, <addr-line><named-content content-type="city">Tarrytown</named-content></addr-line>, <country>United States</country></aff><aff id="aff9"><institution content-type="dept">Regeneron Genetics Center</institution>, <institution>Regeneron Pharmaceuticals</institution>, <addr-line><named-content content-type="city">Tarrytown</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-110520"><name><surname>Lyons</surname><given-names>Karen</given-names></name><role>Reviewing editor</role><aff><country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>aris.economides@regeneron.com</email> (AE);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>vincent.idone@regeneron.com</email> (VI);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>09</day><month>06</month><year>2020</year></pub-date><volume>9</volume><elocation-id>e54582</elocation-id><history><date date-type="received"><day>19</day><month>12</month><year>2019</year></date><date date-type="accepted"><day>08</day><month>06</month><year>2020</year></date></history><permissions><copyright-statement>Â© 2020, Aykul et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Aykul et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-54582-v1.pdf"/><abstract><p>Activin A functions in BMP signaling in two ways: it either engages ACVR1B to activate Smad2/3 signaling or binds ACVR1 to form a non-signaling complex (NSC). Although the former property has been studied extensively, the roles of the NSC remain unexplored. The genetic disorder fibrodysplasia ossificans progressiva (FOP) provides a unique window into ACVR1/Activin A signaling because in that disease Activin can either signal through FOP-mutant ACVR1 or form NSCs with wild type ACVR1. To explore the role of the NSC, we generated 'agonist-only' Activin A muteins that activate ACVR1B but cannot form the NSC with ACVR1. Using one of these muteins we demonstrate that failure to form the NSC in FOP results in more severe disease pathology. These results provide the first evidence for a biological role for the NSC <italic>in vivo</italic> and pave the way for further exploration of the NSC's physiological role in corresponding knock-in mice.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><funding-statement>The authors declare that there was no funding for this work.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Senem Aykul, The author is an employee of Regeneron Pharmaceuticals, Inc.  Regeneron is currently developing a monoclonal antibody that neutralizes Activin A (REGN2477) as a potential therapy in fibrodysplasia ossificans progressiva (see https://clinicaltrials.gov/ct2/show/NCT03188666)..</p></fn><fn fn-type="conflict" id="conf3"><p>Hyonjong Kim, The author is an employee of Regeneron Pharmaceuticals, Inc.  Regeneron is currently developing a monoclonal antibody that neutralizes Activin A (REGN2477) as a potential therapy in fibrodysplasia ossificans progressiva (see https://clinicaltrials.gov/ct2/show/NCT03188666)..</p></fn><fn fn-type="conflict" id="conf4"><p>Qian Zhang, The author is an employee of Regeneron Pharmaceuticals, Inc.  Regeneron is currently developing a monoclonal antibody that neutralizes Activin A (REGN2477) as a potential therapy in fibrodysplasia ossificans progressiva (see https://clinicaltrials.gov/ct2/show/NCT03188666)..</p></fn><fn fn-type="conflict" id="conf5"><p>Ashique Rafique, The author is an employee of Regeneron Pharmaceuticals, Inc.  Regeneron is currently developing a monoclonal antibody that neutralizes Activin A (REGN2477) as a potential therapy in fibrodysplasia ossificans progressiva (see https://clinicaltrials.gov/ct2/show/NCT03188666)..</p></fn><fn fn-type="conflict" id="conf6"><p>Raymond Leidich, The author is an employee of Regeneron Pharmaceuticals, Inc.  Regeneron is currently developing a monoclonal antibody that neutralizes Activin A (REGN2477) as a potential therapy in fibrodysplasia ossificans progressiva (see https://clinicaltrials.gov/ct2/show/NCT03188666)..</p></fn><fn fn-type="conflict" id="conf7"><p>Xin Wang, The author is an employee of Regeneron Pharmaceuticals, Inc.  Regeneron is currently developing a monoclonal antibody that neutralizes Activin A (REGN2477) as a potential therapy in fibrodysplasia ossificans progressiva (see https://clinicaltrials.gov/ct2/show/NCT03188666)..</p></fn><fn fn-type="conflict" id="conf8"><p>Joyce McClain, The author is an employee of Regeneron Pharmaceuticals, Inc.  Regeneron is currently developing a monoclonal antibody that neutralizes Activin A (REGN2477) as a potential therapy in fibrodysplasia ossificans progressiva (see https://clinicaltrials.gov/ct2/show/NCT03188666)..</p></fn><fn fn-type="conflict" id="conf9"><p>Johanna Jimenez, The author is an employee of Regeneron Pharmaceuticals, Inc.  Regeneron is currently developing a monoclonal antibody that neutralizes Activin A (REGN2477) as a potential therapy in fibrodysplasia ossificans progressiva (see https://clinicaltrials.gov/ct2/show/NCT03188666)..</p></fn><fn fn-type="conflict" id="conf10"><p>Kalyan C Nannuru, The author is an employee of Regeneron Pharmaceuticals, Inc.  Regeneron is currently developing a monoclonal antibody that neutralizes Activin A (REGN2477) as a potential therapy in fibrodysplasia ossificans progressiva (see https://clinicaltrials.gov/ct2/show/NCT03188666)..</p></fn><fn fn-type="conflict" id="conf11"><p>Nyanza J Rothman, The author is an employee of Regeneron Pharmaceuticals, Inc.  Regeneron is currently developing a monoclonal antibody that neutralizes Activin A (REGN2477) as a potential therapy in fibrodysplasia ossificans progressiva (see https://clinicaltrials.gov/ct2/show/NCT03188666)..</p></fn><fn fn-type="conflict" id="conf12"><p>John B Lees-Shepard, The author is an employee of Regeneron Pharmaceuticals, Inc.  Regeneron is currently developing a monoclonal antibody that neutralizes Activin A (REGN2477) as a potential therapy in fibrodysplasia ossificans progressiva (see https://clinicaltrials.gov/ct2/show/NCT03188666)..</p></fn><fn fn-type="conflict" id="conf13"><p>Andrew J Murphy, The author is an employee of Regeneron Pharmaceuticals, Inc.  Regeneron is currently developing a monoclonal antibody that neutralizes Activin A (REGN2477) as a potential therapy in fibrodysplasia ossificans progressiva (see https://clinicaltrials.gov/ct2/show/NCT03188666)..</p></fn><fn fn-type="conflict" id="conf14"><p>Aris N Economides, The author is an employee of Regeneron Pharmaceuticals, Inc.  Regeneron is currently developing a monoclonal antibody that neutralizes Activin A (REGN2477) as a potential therapy in fibrodysplasia ossificans progressiva (see https://clinicaltrials.gov/ct2/show/NCT03188666)..</p></fn><fn fn-type="conflict" id="conf15"><p>Vincent Idone, The author is an employee of Regeneron Pharmaceuticals, Inc.  Regeneron is currently developing a monoclonal antibody that neutralizes Activin A (REGN2477) as a potential therapy in fibrodysplasia ossificans progressiva (see https://clinicaltrials.gov/ct2/show/NCT03188666)..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>We are providing source files for the data shown in the main figures of the manuscript.</p></sec><supplementary-material><ext-link xlink:href="elife-54582-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>